Why invest in Royalty Pharma
A unique way to invest in biopharma
Key highlights
Market leader & pioneer
27years
of compounding value
~60%
Share of pharmaceutical royalty market
>80
Royalty acquisitions since founding
Significant funding opportunity
>$1tn
Capital required for biopharma innovation over next decade
Strong track record
~13%
Portfolio Receipts CAGR between 2010-2020
Efficient business model
$3.0bn
Portfolio Receipts (2023)
92%
EBITDA margin
Long duration, diversified portfolio
~13year
Portfolio duration with track record of growing through royalty expirations
15
Blockbuster products (>$1bn in annual sales)
Maximizing biopharma industry strengths and minimizing challenges
Maximizing
- Exposure to transformative therapies
- Revenue and profit diversification
- Therapeutic area breadth
- Long weighted average portfolio duration
- Consistent and sustainable growth
- Management team continuity
- Shareholder alignment
- Opportunity – entire R&D ecosystem is our pipeline
Minimizing
- Early-stage development risk
- R&D and SG&A cost base
- Therapeutic area bias
- Highly competitive business development
- Late-stage clinical binary risk
Investor resources
Watch our inaugural Investor Day 2022
Royalty Pharma Investor Day highlights stronger growth outlook and the power of our unique business model to drive value for all stakeholders.
